Regulator-mandated study finds no link between semaglutide use and pancreatic cancer

AI Summary

A regulator-mandated study using registry data from Denmark, Sweden, and Norway found no association between semaglutide use and pancreatic cancer. The findings were presented at the European Association for the Study of Diabetes annual meeting in Milan.

New research presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, found no link between semaglutide use and pancreatic cancer in nationwide registry data from Denmark, Sweden and Norway. The regulator-mandated post-authorization study was presented by Anton Pottegård, a professor at the University of Southern Denmark in Odense, and colleagues.